Millions of older Americans will gain Medicare coverage for GLP-1 weight-loss drugs starting July 1. This marks the first time the program has covered these medications specifically for obesity.
The policy change opens access to popular drugs like Wegovy and Zepbound. These medications were previously limited to treating diabetes or other conditions under Medicare.
Beneficiaries should consult their doctors about eligibility. A formal obesity diagnosis will likely be required for coverage.
Cost remains a significant factor. Even with Medicare, out-of-pocket expenses may still apply under Part D plans.
Side effects warrant careful consideration. Common issues include nausea, vomiting, and diarrhea, which can be more serious for older adults.
Drug interactions are another concern. Seniors often take multiple medications that may conflict with GLP-1s.
Long-term weight maintenance is crucial. These drugs typically require ongoing use to sustain results, so patients should plan accordingly.
Medicare coverage does not guarantee immediate access. Beneficiaries may need prior authorization from their plan.
The rollout could face supply constraints. High demand has already caused shortages for some GLP-1 medications.
Experts recommend starting discussions with healthcare providers now. This allows time for necessary paperwork and medical evaluations before July 1.
